ArticleBiochemistry and biophysics reports2025
PIK3C2B drives lung cancer progression through coordinating metabolic reprogramming and EMT-mediated metastasis.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide, is driven by metastatic dissemination and metabolic adaptation. However, the underlying mechanisms remain poorly understood. This study identifies PIK3C2B, an understudied isoform of PI3K, as a key regulator of these processes. Integrative transcriptomics analysis of eight GEO datasets revealed 336 consistently dysregulated genes, with PIK3C2B emerging as a candidate associated with metastasis. Elevated expression of PIK3C2B was correlated with reduced overall survival (log-rank p < 0.05) and shorter disease-free survival (p < 0.05) in lung adenocarcinoma patients. Immunohistochemistry confirmed PIK3C2B overexpression in patient tumors. Functional validation showed that silencing PIK3C2B impaired proliferation and migration, while its overexpression enhanced these phenotypes. Mechanistically, PIK3C2B expression was correlated with epithelial-to-mesenchymal transition (EMT) regulators, suggesting its role in mesenchymal transition. Metabolic profiling using Seahorse analysis revealed that PIK3C2B enhanced mitochondrial oxidative phosphorylation (increased basal OCR and ATP production) and glycolytic flux (and fatty acid metabolism). Our findings establish PIK3C2B as a dual-function oncoprotein that promotes lung cancer progression through EMT activation and bioenergetic reprogramming. Its prognostic significance and role in metabolic adaptability highlight PIK3C2B as a promising therapeutic target for disrupting metastasis and enhancing tumor resilience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.